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Wedeveloped, implemented, and evaluated amyocardial infarction (MI) adjudication protocol for cohort research
of human immunodeficiency virus. Potential events were identified through the centralized Centers for AIDS Re-
search Network of Integrated Clinical Systems data repository using MI diagnoses and/or cardiac enzyme labora-
tory results (1995–2012). Sites assembled de-identified packets, including physician notes and results from
electrocardiograms, procedures, and laboratory tests. Information pertaining to the specific antiretroviral medica-
tions used was redacted for blinded review. Two experts reviewed each packet, and a third review was conducted
if discrepancies occurred. Reviewers categorized probable/definite MIs as primary or secondary and identified sec-
ondary causes of MIs. The positive predictive value and sensitivity for each identification/ascertainment method
were calculated. Of the 1,119 potential events that were adjudicated, 294 (26%) were definite/probable MIs. Almost
as many secondary (48%) as primary (52%) MIs occurred, often as the result of sepsis or cocaine use. Of the pa-
tients with adjudicated definite/probable MIs, 78% had elevated troponin concentrations (positive predictive
value = 57%, 95% confidence interval: 52, 62); however, only 44% had clinical diagnoses of MI (positive predictive
value = 45%, 95% confidence interval: 39, 51). We found that central adjudication is crucial and that clinical diag-
noses alone are insufficient for ascertainment of MI. Over half of the events ultimately determined to beMIs were not
identified by clinical diagnoses. Adjudication protocols used in traditional cardiovascular disease cohorts facilitate
cross-cohort comparisons but do not address issues such as identifying secondary MIs that may be common in
persons with human immunodeficiency virus.
HIV; myocardial infarction; validation
Abbreviations: ARV, antiretroviral medication; CNICS, Centers for AIDS Research Network of Integrated Clinical Systems; CVD,
cardiovascular disease; ECG, electrocardiogram; EHR, electronic health record; HIV, human immunodeficiency virus; MESA,
Multi-Ethnic Study of Atherosclerosis; MI, myocardial infarction; NA-ACCORD, North American AIDS Cohort Collaboration on
Research and Design.
Many questions remain unanswered about the risk of
cardiovascular disease (CVD), and particularly myocardial
infarction (MI), in persons living with human immuno-
deficiency virus (HIV). Antiretroviral therapy has reduced
morbidity and mortality rates among persons living with
HIV (1–4), but it has also been thought to increase CVD
risk (5, 6). However, the Strategies for Management of Anti-
retroviral Therapy (SMART) Study found that CVD inci-
dence is lower among persons who receive uninterrupted
treatment than among thosewho receive delayed or intermittent
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antiretroviral therapy (7). HIV infection may alter lipid metab-
olism and worsen endothelial function, and it is associated with
greater carotid intimamedial thickness, which can lead to CVD
(8–11). Additional studies are needed to further understand the
impact of HIV and its treatment on CVD.
The study of CVD requires clearly defined clinical end-
points and accurate identification of events. Identification
of CVD events among HIV-uninfected individuals using
data from electronic health records (EHRs) is complex and
prone to errors (12). Therefore, some studies have conducted
CVD event adjudication (13–15) because it improves accu-
racy in comparison with more streamlined endpoint ascer-
tainment (16–18). However, in many studies of CVD and
HIV, investigators relied on administrative diagnosis codes
and other nonadjudicated outcomes (19–24) that are known
to lead to the misclassification and overestimation of true
event rates (25–27).
We developed and implemented an MI adjudication proto-
col for HIV cohort research in the Centers for AIDS Research
Network of Integrated Clinical Systems (CNICS) cohort
(28). TheMI protocol addresses issues that are specific to per-
sons with HIV and enables comparisons with traditional
CVD cohort studies. A central, independent review commit-
tee adjudicates all suspected MIs identified by screening
comprehensive clinical data while blinded to potential con-
founders, such as use of particular antiretroviral medications
(ARVs). We evaluated the sensitivity and positive predictive
value of different criteria that could be used to ascertain po-
tential MI events, using adjudication as the gold standard.
METHODS
Study cohort
The present observational study was conducted in the
CNICS cohort, which includes more than 27,000 persons liv-
ing with HIV and receiving care at 8 clinical sites across the
United States from 1995 to the present (28). All participating
sites provide primary and subspecialty care and have EHRs
that span both inpatient and outpatient settings. Potential
MI events from 5 sites (University of Alabama at Birming-
ham, Birmingham, Alabama; University of Washington, Se-
attle, Washington; University of California at San Diego, San
Diego, California; University of North Carolina at Chapel
Hill, Chapel Hill, North Carolina; and Johns Hopkins Uni-
versity, Baltimore, Maryland) were included in this analysis.
We included all events adjudicated between March 2010 and
December 2012; event dates were between January 1, 1996,
and January 6, 2012. Sites received institutional review board
approval for the CNICS Study.
CNICS data
The CNICS data repository systematically captures demo-
graphic, clinical, medication, and laboratory data for all pa-
tients receiving care at each CNICS site from the EHRs
and other institutional data systems (28). Clinical diagnoses
are recorded in the EHRs by the treating physician using stan-
dardized diagnoses and International Classification of Dis-
eases, Ninth Revision, coding. Data quality assessment is
conducted at the sites before data transmission and at the
time of submission to the Data Management Core before in-
sertion into the central repository. Data undergo extensive
quality-assurance procedures, and data quality issues are re-
ported to sites to be investigated and corrected. Data from
each site are updated, reviewed, and integrated into the repos-
itory quarterly (28).
Ascertainment of potential MI events
Potential MI events are identified centrally for review
based on a standard protocol applied to laboratory and diag-
nosis data in the CNICS data repository. Criteria for ascer-
tainment of a potential MI event included: 1) inpatient or
outpatient clinical MI diagnosis of an acute or unspecified
timeframe (such as International Classification of Diseases,
Ninth Revision, codes 410.00, 410.01, and 410.10) and/or
2) cardiac enzyme elevation above the laboratory-specific
upper limit of normal for troponin-I, troponin-T, and creatine
kinase MB. Use of specific cardiac enzyme tests varied by
site and over time. One or more elevated values of any of
these was sufficient to meet ascertainment criteria.
As part of protocol development, we also examined all po-
tential events (n = 48) at one site (University of Washington)
that could be identified by additional diagnosis and procedure
codes (such as codes 37.22, 37.23, 411.0, 411.1, 414.04, and
428.0), including congestive heart failure, cardiac catheteri-
zation, or coronary artery bypass graft surgery. Adding
these criteria resulted in no additional adjudicated MIs be-
yond those already identified; therefore, these additional
codes were not included in the ascertainment criteria.
MI review packet assembly
For every potential MI event that was identified, investiga-
tors from each site assembled a standardized set of comput-
erized clinical information (in the form of Adobe PDF or
compressed documents) for central review that contained
the following:
• Physician’s notes made closest to the potential MI date, in-
cluding admission, transfer, discharge, clinic, and emer-
gency department notes, inpatient cardiology consultation
notes, and autopsy reports;
• Documentation pertaining to the first 3 outpatient cardiol-
ogy consultations or visits after the potential MI date;
• Baseline electrocardiogram (ECG) (before the MI date), if
available;
• First 2 ECGs after admission or event date (includes ECGs
obtained in the emergency department), the last ECG
before discharge, and the last ECG recorded on day 3 (or
the first ECG thereafter) after admission or in-hospital
event;
• Results from related procedure and diagnostic tests per-
formed around and after the potential MI event, including
stress test, cardiac echocardiography, cardiac radionuclide
imaging, cardiac magnetic resonance imaging, cardiac
computed tomography, and cardiac catheterization results,
as well as operative reports from coronary artery bypass
graft surgery; and
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• Related laboratory values measured near the potential MI
event, including creatine kinase MB and troponin results.
Information regarding which ARVs had been prescribed was
redacted from the packet. Completed packets were uploaded
to the CNICS web-based MI platform. Investigators at the
sites were asked to document reasons for missing and incom-
plete packets, such as potential events that occurred outside
the hospital system, and were asked to make 2 attempts to
obtain outside records before declaring information unavail-
able. Investigators could also document when the ascertain-
ment of an MI was an error, thereby precluding the need to
assemble data. Finally, if ascertainment identified an event
that was determined to have occurred previously, investiga-
tors were asked to identify the approximate timing of the ear-
lier event. A new packet request was generated with the
earlier event date.
Packet data were available for review to users with appro-
priate permissions managed through an open standards-
compliant, secure, federated single sign-on identity service
(http://www.protectnetwork.org/), using an application that
permits review of the data and assignment of adjudication re-
sults into a database linked by CNICS study identifiers. This
supports easy, distributed access to the adjudication packets
and efficient management of adjudication results while al-
lowing reviewers to be selected without regard for physical
location.
MI adjudication criteria
The criteria used to classify events included reports of
chest pain, elevated cardiac enzymes, and abnormal ECGs.
The CNICS MI criteria were adapted from the Multi-Ethnic
Study of Atherosclerosis (MESA) (14) and the universal MI
definition (29) with input from experts in the field, including
MESA investigators. Aweb application designed for CNICS
MI adjudication enabled reviewers to classify the MI event
and enter additional standardized data. Capturing standard-
ized review criteria provided the flexibility to apply different
operational MI definitions. Cardiac chest pain was defined as
an episode of ischemic pain, tightness, pressure, or discom-
fort in the chest, arm, or jaw of any duration. Atypical pain
that was determined to be due to coronary ischemia also qual-
ified as cardiac chest pain. Chest pain was considered absent
if the pain was due to a clear noncardiac cause. Cardiac en-
zyme concentrations were classified as normal, equivocal, or
abnormal based on the most elevated value. Different cut-
points were used for cardiac enzyme levels in patients who
had undergone a coronary artery bypass graft surgery or per-
cutaneous transluminal coronary angioplasty within the prior
48 hours or who had muscle trauma. Reviewers also identi-
fied whether a patient had regional wall abnormalities identi-
fied on imaging (if available).
MI adjudication
Members of the CNICS MI adjudication committee are
physicians participating in MESA and other CVD cohort
studies and are thus experienced MI event reviewers. Train-
ing calls were conducted to ensure understanding of the
protocol. All reviewers adjudicated the same initial group
of events, and discrepancies between reviewers were dis-
cussed. After the initial training period, 2 reviewers adjudi-
cated each event, followed by a third reviewer in cases of
discrepancy. Each potential event was categorized by review-
ers as definite, probable, no/absent, or no with resuscitated
cardiac arrest. For potential events classified as non-MIs
(no/absent), reviewers documented whether the patient had
undergone a cardiac intervention, such as a coronary artery
bypass graft surgery, percutaneous transluminal coronary an-
gioplasty, or stent placement. Adapting and expanding prior
MI protocols, reviewers categorized probable/definite MIs as
primary spontaneous events or secondary events that oc-
curred because of some other cause, such as sepsis, and se-
lected a cause for each secondary MI from a standardized
list. For some potential MI events, cardiac enzyme elevation
was felt to be related to a cause other than MI; reviewers la-
beled such events as “false positives” and specified the sus-
pected other cause.
Analysis
We examined the number and percentages of events that
required third reviews, were adjudicated to be primary versus
secondary events, or had false-positive enzyme elevation.We
calculated κ statistics as a measure of agreement between 2
reviewers beyond chance alone (30). A priori, we defined
κ < 0.4 as poor to fair agreement, 0.41–0.60 as moderate
agreement, 0.61–0.80 as substantial agreement, and 0.81–
1.0 as excellent agreement, as was done previously (15,
31). We calculated the positive predictive value, which is
the proportion of MIs reported by each ascertainment method
(clinical MI diagnosis, elevated cardiac enzymes) that were
verified by adjudication, and the sensitivity, which is the pro-
portion of true MIs verified by adjudication that were identi-
fied as positive by each ascertainment method (30). We
combined probable and definite MIs for these analyses. We
report exact binomial 95% confidence intervals.
Our primary analyses focused on persons with diagnoses
or elevated cardiac enzymes that were suggestive of an MI.
Additionally, to further evaluate our approach, a random
sample of 100 patients from one site without diagnoses or
elevated cardiac enzyme levels was also reviewed for MI
events.
RESULTS
There were 1,119 potential MI events identified by an ele-
vated enzyme level and/or clinical MI diagnosis adjudicated
during the study period. Among all potential events, 75%
were in men, the mean age of subjects was 47 (standard de-
viation, 9) years, and the current mean CD4 cell count (at the
time of the potential MI event) was 298 (standard deviation,
265) cells/mm3 (Table 1).
Of 1,119 potential events, 202 (18%) were adjudicated as
definite MIs, 92 (8%) were adjudicated as probable MIs, and
another 9 (<1%) were adjudicated as resuscitated cardiac ar-
rests using theMESA definition. Of the 294 definite/probable
MIs, 153 (52%) were adjudicated to be primary and 141
(48%) were considered secondary. Sepsis (38 MIs, 34% of
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secondary MIs) and vasospasm related to use of cocaine or
other illicit drugs (20 MIs, 14%) were the most common
causes of secondary MIs. Other common causes (ranging
from 5% to 10% of the secondary MIs) included hypoten-
sion, hypertensive urgency/emergency, arrhythmias, and
gastrointestinal bleeding.
Table 1. Clinical and Demographic Characteristics of Patients Who Met Ascertainment Criteria for a Potential
Myocardial Infarction Event by Event Adjudication Outcome (n = 1,119), Centers for AIDS Research Network of







(n = 202) P Valueb
No. % No. % No. %
Sex 0.1
Male 634 77 62 67 157 78
Female 191 23 30 33 45 22
Age, years 0.02
<40 152 18 23 25 28 14
40–50 368 45 43 47 85 42
50–60 242 29 20 22 60 30
≥60 63 8 6 7 29 14
Race 0.6
White 270 33 31 34 79 39
African-American 485 59 56 61 109 54
Hispanic 48 6 3 3 11 5
Other 22 3 2 2 3 2
Risk factor for HIV transmission <0.01
Being a MSM 205 25 28 30 67 33
Injection drug use 392 48 40 44 59 29
Being heterosexual 203 25 20 22 61 30
Other/unknown 18 2 4 4 15 7
CD4 cell count,c current cells/mm3 0.3
0–200 357 43 47 51 84 42
201–350 172 21 17 19 35 17
>350 295 36 28 30 83 41
CD4 cell count,c nadir cells/mm3 0.1
0–200 573 70 69 75 133 66
201–350 151 18 11 12 32 16
>350 100 12 12 13 37 18
HIV-1 RNA,d copies/mL 0.8
>100,000 191 23 24 26 43 21
10,000–100,000 163 20 21 23 39 20
<10,000 468 57 47 51 119 59
Body mass indexe 0.3
<18.5 80 10 11 12 25 13
18.5–24 411 50 53 58 92 46
25–30 215 26 16 18 51 25
>30 116 14 11 12 33 16
Abbreviations: HIV, human immunodeficiency virus; MI, myocardial infarction; MSM, man who has sex with men.
a Falsely positive events were included in the no MI category.
b P value for the difference between definite/probable and no MI.
c CD4 values were available for 1,118 events.
d HIV RNA levels were available for 1,115 events.
e Weight in kilograms divided by height in meters squared. Measurements were available for 1,114 events.
Height measurements were available for 957 events. Median height by sex and age group were imputed for the
remaining 157 events.
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We examined the standardized review criteria entered by
reviewers for the 294 definite/probable MIs. Chest pain was
identified for 164 (56%), abnormal ECGs were present for
190 (65%), and elevated cardiac enzymes were identified
for 287 (98%). Only 64 (22%) events had regional wall
abnormalities identified on imaging.
Ascertainment criteria
Adjudicated events could have been identified by more
than one ascertainment/identification criterion from the
CNICS data repository. Of the 294 definite/probable MIs,
89% were identified by elevated cardiac enzymes, of which
78% had elevated troponin levels and 65% had elevated cre-
atine kinase MB levels (some had both). Less than half (44%)
of adjudicated definite/probable MIs were identified by a clin-
ical MI diagnosis (Table 2). Among the 294 definite/probable
MIs, 70% of primary MIs were identified by a clinical MI di-
agnosis, whereas only 23% of secondary MIs were. Elevated
troponin values had the highest positive predictive value
(57%) (Table 2). Sensitivity and positive predictive value
did not differ meaningfully by age for persons with elevated
troponin or creatine kinase MB values; however, among pa-
tients less than 50 years of age, the sensitivity and positive
predictive value for clinical MI diagnoses (39% and 42%, re-
spectively) were lower than those among patients 50 years of
age or older (51% and 50%, respectively).
There were 128 events (11%) that met MI criteria but were
identified clinically as occurring in persons who had an en-
zyme elevation because of a cause other than acute cardiac
ischemia, such as renal failure (Table 3). As the result of
the adjudication process, these events were categorized as
falsely positive and not included as MIs.
Discrepancies in some aspect of the review requiring a
third review were present for 255 possible events (22%)
(MI vs. no MI; definite vs. probable MI; primary vs. second-
aryMI; falsely positive vs. not). κ statistics between the first 2
reviewers were 78%–84%, indicating substantial to excellent
agreement. Of 100 randomly selected patients without any
Table 2. Ascertainment (Test) Criteria Used to Identify Events Categorized by Myocardial Infarction Adjudication











Definite) P Value % 95% CI % 95% CI
No. % No. % No. %
MI diagnosis
No 549 79 121 95 166 56 <0.001 44 38, 49 45 39, 51
Yes 148 21 7 5 128 44
Elevated CK-MB value
No 196 28 82 64 102 35 <0.001 65 60, 71 26 23, 29
Yes 501 72 46 36 192 65
Elevated troponin value
No 639 92 15 12 65 22 <0.001 78 73, 83 57 52, 62




No 158 23 0 0 31 11 <0.001 89 85, 93 28 25, 31
Yes 539 77 128 100 263 89
Abbreviations: CI, confidence interval; CK-MB, creatine kinase MB; MI, myocardial infarction.
a A false positive was recoded as no event.
b Estimates were assessed among persons who tested positive on at least 1 of 3 criteria. No patients identified as
negative by the 3 criteria were included in the analysis; as such, estimates of specificity and negative predictive value
are unavailable.
Table 3. Causes of Potential False Positive Results (n = 128),
Centers for AIDS Research Network of Integrated Clinical Systems,
1995–2012
Cause No. %
Renal failure 75 59
Congestive heart failure 15 12
Severe sepsis/shock 12 9
Pulmonary embolism 6 5
Pericarditis 4 3
Myocarditis 1 1
All other causes 16 12
1000 Crane et al.
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ascertainment criteria suggestingMI, no events were detected
(0%, 95% confidence interval: 0, 3.6).
DISCUSSION
We developed, implemented, and evaluated aMI adjudica-
tion protocol for HIV that was conducted by centralized ex-
pert reviewers who were blinded to the exposures of interest.
Among the first 1,119 potential events, 294 were adjudicated
as definite/probable MIs. Ascertainment criteria for 89% of
definite/probable MIs included elevated cardiac enzymes,
and 78% of patients with definite/probable MIs had elevated
troponin values. Only 44% had a clinical MI diagnosis, dem-
onstrating the insensitivity of clinical diagnoses and the im-
portance of multiple ascertainment criteria. Furthermore,
secondary MIs (48%) were almost as common as primary
events (52%), highlighting the importance of identifying
MI type. After reviewing packets that could include informa-
tion from outside medical records, 98% of adjudicated MIs
included elevated cardiac enzymes as MI criteria.
Definitions
These analyses used MESAMI case definitions. Case def-
initions vary across studies and continue to evolve, such as
with the universal MI definition, which has led to the appear-
ance of increasing MI incidence rates over time (29, 32–37).
Although the impact is small, MESA and universal MI defi-
nitions use different thresholds to define cardiac enzyme ele-
vations after a coronary artery bypass graft surgery. This has
been a controversial area with limited data (38), suggesting a
need to reevaluate current definitions (39). Reviewers enter
MI criteria for each case into the adjudication platform, facil-
itating future analyses that use different criteria as MI defini-
tions continue to evolve (33, 34).
Ascertainment and adjudication
Comprehensive clinical data in the CNICS repository
facilitated more focused, thorough, and efficient MI ascer-
tainment than was possible in previous studies (13, 15, 40)
that may have had to obtain medical records from essentially
every hospitalization. Consistent with prior studies, we found
that using multiple criteria to identify potential events in-
creased the number of events that were identified (41). How-
ever, we did not find that including related CVD diagnoses or
procedures increased the number of cases, which was in con-
trast to prior studies (15, 42). The enhanced sensitivity of our
approach may be due to the use of cardiac enzyme levels in
addition to diagnoses.
Adjudication resulted in identifying false-positive events
that would have been coded as an MI event in studies relying
on nonadjudicated definitions, such as MI billing diagnosis
codes (41, 43–45). One study found that diagnosis codes un-
derestimatedMIs identified through chart review by half (46).
We found that only 44% of true events were identified by
MI diagnosis codes, and these codes worked less well among
younger patients. Secondary MIs in particular were frequently
missed. In fact, MI diagnoses identified more non-MI events
than events adjudicated to be definite/probable MIs. Elevated
cardiac enzymes, particularly troponin levels, provided the
highest level of accuracy but were still problematic, as 11%
of potential events had falsely positive enzyme elevations.
This highlights the need for adjudication and additional stud-
ies comparing event rates between adjudicated and nonadju-
dicated events.
Central adjudication is preferable to local event adjudica-
tion with or without secondary central review. Previous stud-
ies found that outcome rates vary depending on whether
committees merely confirm events reported by local sites or
adjudicate all potential events identified by systematic review
of comprehensive clinical data as we did. The higher MI rates
found in studies using central adjudication versus those rely-
ing on onsite clinicians/investigator reviews (47–50) have re-
sulted in meaningful differences across studies (47, 50–52).
MI misclassification has been attributed to reluctance by re-
viewers to apply all aspects of standard MI definitions (41)
and to misreporting of MI endpoints (49, 52, 53). Central as-
certainment and adjudication has been particularly important
in heterogeneous geographic regions and settings in which
there is risk of applying varying MI definitions despite estab-
lished protocols (51).
Secondary MIs
It is important to distinguish primary spontaneous MI
events from events that occur secondary to other clinical syn-
dromes in the setting of ischemia due to increased oxygen de-
mand or decreased supply, such as severe hypotension (54).
Secondary MIs are categorized as type 2MIs by the universal
MI definition (with the exception of those that are secondary
to certain procedures, which are type 4 or 5) (37) and have
treatment implications distinct from those of primary MIs
(55). We found high numbers of secondary MIs due to sepsis
or vasospasm associated with cocaine use. Although few
studies have examined type 2 MIs, we found that close to
half of the events in a population of persons living with
HIV were type 2 events, in contrast to a recent general pop-
ulation study which found that a quarter of events were type 2
(56). Identifying these events may be particularly important
among persons living with HIV, in whom secondary MI rates
may be higher than in other patient populations.
False-positive MIs
False-positive events were due to isolated enzyme eleva-
tions without other evidence for MI. Reasons identified in-
cluded pericarditis, pulmonary embolism, heart failure, or
renal failure, though reasons for elevations may differ
for troponin-T versus troponin-I (57). Many studies cannot
distinguish these events from MIs. Identifying these events
may be particularly important in studies of persons living
with HIV; this highlights the need for adjudication that incor-
porates clinical context rather than just using endpoint
ascertainment.
Blinding
The CNICS MI protocol blinds reviewers to key covari-
ates, such as which individual ARVs were prescribed to
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patients. Blinding addresses the possibility of differential ad-
judication based on the reviewer’s belief that a particular
ARV, such as abacavir, may be more likely to be associated
with MI (41, 58, 59). The influence of a reviewer’s knowl-
edge of ARV exposure on adjudication is not known and
may be of particular importance given the number of conflict-
ing studies regardingARVs, such as abacavir, andMIs (60–64).
Blinding reviewers to individual ARVs requires additional
time for redaction of primary records. Blinded central adjudi-
cation addresses differential misclassification only if the site
clinicians/investigators are ascertaining and reporting infor-
mation without bias (41). Therefore, after centralized event
ascertainment, sites upload primary notes and reports cen-
trally for distribution rather than synthesizing information
onto event forms, which could result in bias because site
clinicians are not blinded to ARVs (41).
Web-based adjudication system
The CNICS web-based system used to adjudicate MIs and
other endpoints improves review efficiency by eliminating
the need to mail forms. Electronic data entry facilitates auto-
mated checks for missing data and comparisons between re-
views. This system allows skip patterns such that reviewers
are only asked about adjudication criteria for persons found
to have had an event and allows use of dropdown menus that
include common reasons for false-positive events, thereby
decreasing review time and improving data quality.
Limitations
A potential limitation is the lack of self-report for MIs,
which could allow missed cases. However, one study found
that of 276 self-reported CVD events, only 68%were verified
by adjudication of medical records (65). Among self-reported
MIs, 50% were confirmed, 29% were adjudicated as angina
or other non-MI coronary event, and 21% were determined
not to be a coronary event (65). Sensitivity for self-reported
MI is low (66). Medical record data has traditionally been
used as the gold standard for self-report validation (66, 67),
and thus it is unclear if self-report would increase identifica-
tion beyond the use of comprehensive EHR data. Symptom-
atic MIs tend to present as dramatic painful events that require
hospitalization, and therefore information should be readily
available in both medical record data and self-report. How-
ever, the potential for ascertainment of secondary MI events
occurring in the setting of sepsis or other hospitalizations
suggests that medical record data ascertainment may be
more comprehensive in studies of persons living with HIV.
A limitation of our approach is that research costs continue
to climb and MI adjudication consumes resources. Not all
studies have demonstrated that endpoint adjudication has a
clear impact on estimates (41), although there is little doubt
that it increases accuracy (68). Although we did not conduct a
formal cost estimate, the CNICS MI protocol is more time-
intensive than using coded EHR data without adjudication.
However, the number of related diagnosis codes makes end-
point ascertainment alone complicated and inaccurate with-
out adjudication (12). The CNICS web-based adjudication
platform greatly reduced administrative time and burden,
thereby decreasing costs. The requirement for 2 reviewers
for each event also contributes to cost. However, although
some protocols have selected subsamples of charts for review
(33), we found that double review of all charts was worth the
investment because for approximately 1 of every 5 of events,
there were discrepancies between reviewers.
We did not systematically ascertain ECGs to look for silent
events. Using ECGs to look for past MIs has very low detec-
tion probability, even among patients with confirmed MIs
(69). Researchers minimized the number of missed events
by requesting records from outside hospitals when possible,
but there may still have been events missed. The use of car-
diac enzymes in clinical care and MI definitions has changed
over time, leading to increasing numbers of events meeting
broader MI definitions (55). To minimize the impact of
changing clinical definitions, we ascertained potential events
using cardiac enzymes and not just diagnoses.
Finally, even though this protocol validation includes data
from multiple sites across the United States, the findings
have not been replicated more broadly. Although we reported
several measures of accuracy, we note that measures such as
positive predictive value depend on the disease prevalence
within the population (70). However, because we reviewed
records for every patient with elevated enzymes, which is
the key to modern MI definitions, it is likely that few non-
silent MIs were missed. Because we included only potential
events, negative results were not included, and thus we
did not calculate specificity and negative predictive value.
However, no events were identified among 100 randomly
sampled patients from one site who had neither clinical diag-
noses nor elevated cardiac enzymes, which suggests that
given the low prevalence of the outcome, the estimated spe-
cificity for each ascertainment criteria would be 97% or
higher.
Strengths
Event adjudication conducted in the present study was
based on theMESA protocol (71) and universal MI definition
(29). As noted above, because reviewers identified relevant
MI criteria for each event, we were able to apply each defini-
tion or other definitions to facilitate cross-study comparisons.
Although ECGs and procedure notes must still be obtained
for adjudication, the use of comprehensive EHR data, includ-
ing inpatient and outpatient information, greatly decreases
the likelihood of there being missing data. CNICS includes
a large and ethnically diverse cohort of patients with the
full range of HIV disease. CNICS addresses several limita-
tions of prior cohort studies. It includes predominantly pro-
spective data collection, which decreases recall bias and
exposure misclassification, and uses standardized data collec-
tion, verification, and adjudication, which minimizes mis-
classification and missing data.
North American AIDS Cohort Collaboration on Research
and Design
We have extended the MI protocol used in CNICS to mul-
tiple sites in the North American AIDS Cohort Collaboration
on Research and Design (NA-ACCORD) cohort (72), the
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largest multicenter HIV cohort collaboration worldwide. Ap-
plying the same MI protocol and outcome definitions across
CNICS and NA-ACCORD strengthens future collaborations
that use combined data for analyses. Although there is some
overlap between the 2 cohorts, each also has independent
sites, which greatly enhanced the potential analytic power.
In addition, data collected in the 2 cohorts are complementary.
CNICS provides detailed patient-reported data such as the rou-
tine measurement of physical activity levels that is not avail-
able in other cohorts. NA-ACCORD provides the very large
sample size required to answer key questions related to HIV
and CVD that cannot be addressed in smaller cohorts.
Conclusions
The MI adjudication protocol described here includes sys-
tematic centralized ascertainment and comprehensive central
adjudication. We demonstrated that adjudication impacts
conclusions drawn about MIs in HIV cohort research. Clini-
cal diagnoses alone are insufficiently sensitive for MI event
ascertainment, as over half of events adjudicated to be prob-
able/definite MIs were not identified by an MI diagnosis
code. Secondary events were almost as common as primary
events. These findings suggest that failure to differentiate pri-
maryMIs from secondary MIs could lead to misclassification
and false conclusions. Cardiac enzyme elevations that were
determined using comprehensive laboratory data led to better
capture of events than did clinical diagnoses alone. Neverthe-
less, 11% of events were in patients with false-positive enzyme
elevation. Blinding to key covariates, identifying discrepancies
through the use of multiple centralized reviewers, and dis-
tinguishing primary from secondary MI events were key
strengths of the approach. Ongoing careful event adjudication
and comprehensive clinical data in CNICS will facilitate a nu-
anced and thorough investigation of the epidemiology of MIs
among persons living with HIV across the United States.
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